公开(公告)号：US20210315882A1

公开(公告)日：2021-10-14

申请号：US17344314

申请日：2021-06-10

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thierry BILBAULT ,  Bradford Armando NAVIA ,  Charles Warren OLANOW

IPC: A61K31/473 ,  A61K9/00 ,  A61P25/16

Abstract: Methods of treating a patient having Parkinson's disease, including treating “OFF” episodes and improving motor function, by administering apomorphine or a pharmaceutically acceptable salt thereof are disclosed herein. Supratherapeutic doses of apomorphine may be used. Apomorphine therapy may be used in place of levodopa therapy, or apomorphine may be used to supplant or augment the first levodopa dose of the day. Apomorphine therapy may involve administration of two consecutive apomorphine doses at least 2 hours apart.

公开(公告)号：US20220241156A1

公开(公告)日：2022-08-04

申请号：US17622046

申请日：2020-06-26

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thierry BILBAULT ,  Arthur TONG

IPC: A61J7/00 ,  A61K9/70 ,  A61J1/00 ,  B65D50/00

Abstract: Product containers, especially child-resistant product dispensers, and methods of use thereof. In some particular embodiments, provided herein are child-resistant medication dispensers, and methods of use thereof for administering medications to individuals that may suffer from manual dexterity problems. The disclosure is particularly useful in dispensing orally dissolving medications intended for sublingual application, such as orally dissolving strips. In one embodiment of the disclosure a medication dispenser is disclosed comprising a container having an opening and an inner chamber, a cap configured to close the opening of the container and provide a child-resistant locking engagement with the container, and a tray deployable in the chamber of the container and configured to hold at least one pouch carrying a dose of medication. The tray can include a support configured to hold one or more pouches when the tray and pouches are deployed within the container.

公开(公告)号：US20210205208A1

公开(公告)日：2021-07-08

申请号：US17179053

申请日：2021-02-18

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David BARNHART ,  Michael Clinton KOONS ,  Madhu Sudan HARIHARAN ,  Jordan DUBOW ,  Thierry BILBAULT ,  Anthony John GIOVINAZZO

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K47/14 ,  A61K47/26 ,  A61K9/70 ,  A61K47/36 ,  A61K45/06 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.

公开(公告)号：US20210179561A1

公开(公告)日：2021-06-17

申请号：US17181043

申请日：2021-02-22

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Thierry BILBAULT

IPC: C07D221/18 ,  A61K9/20 ,  A61K9/00

Abstract: Acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, and acid addition salt of apomorphine isobutyrate salts are disclosed. Also disclosed are pharmaceutical compositions (e.g., unit dosage forms, e.g., films) containing acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate. Further disclosed are methods of use of acid addition salt of apomorphine glycolate, acid addition salt of apomorphine sulfamate, or acid addition salt of apomorphine isobutyrate.

公开(公告)号：US20200069571A1

公开(公告)日：2020-03-05

申请号：US16564864

申请日：2019-09-09

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Scott David BARNHART ,  Michael Clinton KOONS ,  Madhu Sudan HARIHARAN ,  Jordan DUBOW ,  Thierry BILBAULT ,  Anthony John GIOVINAZZO

IPC: A61K9/00 ,  A61K47/02 ,  A61K31/473 ,  A61K47/14 ,  A61K47/26 ,  A61K9/70 ,  A61P25/16 ,  A61K47/10 ,  A61K47/18 ,  A61K47/38 ,  A61K47/36 ,  A61K45/06

Abstract: Methods and pharmaceutical unit dosage forms for treating Parkinson's disease in a subject (e.g., an “off” episode in a subject having Parkinson's disease) are described. The pharmaceutical unit dosage forms are films having a first portion including particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent. The pharmaceutical unit dosage forms can be flexible and have toughness greater than 100 g×mm. The methods can involve administering to a subject having Parkinson's disease a therapeutic dose sufficient to produce an apomorphine plasma concentrate of at least 2.64 ng/mL within 45 minutes after the administration. The subject may be identified as having low uptake, medium uptake, or high uptake of apomorphine administered via oral mucosa.